These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12148568)

  • 1. The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer.
    Achen MG; Williams RA; Baldwin ME; Lai P; Roufail S; Alitalo K; Stacker SA
    Growth Factors; 2002 Jun; 20(2):99-107. PubMed ID: 12148568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
    Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
    J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.
    He Y; Kozaki K; Karpanen T; Koshikawa K; Yla-Herttuala S; Takahashi T; Alitalo K
    J Natl Cancer Inst; 2002 Jun; 94(11):819-25. PubMed ID: 12048269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular control of lymphatic metastasis.
    Achen MG; Stacker SA
    Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer.
    Von Marschall Z; Scholz A; Stacker SA; Achen MG; Jackson DG; Alves F; Schirner M; Haberey M; Thierauch KH; Wiedenmann B; Rosewicz S
    Int J Oncol; 2005 Sep; 27(3):669-79. PubMed ID: 16077915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics.
    Stacker SA; Caesar C; Baldwin ME; Thornton GE; Williams RA; Prevo R; Jackson DG; Nishikawa S; Kubo H; Achen MG
    Nat Med; 2001 Feb; 7(2):186-91. PubMed ID: 11175849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man.
    Baldwin ME; Catimel B; Nice EC; Roufail S; Hall NE; Stenvers KL; Karkkainen MJ; Alitalo K; Stacker SA; Achen MG
    J Biol Chem; 2001 Jun; 276(22):19166-71. PubMed ID: 11279005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D.
    McColl BK; Baldwin ME; Roufail S; Freeman C; Moritz RL; Simpson RJ; Alitalo K; Stacker SA; Achen MG
    J Exp Med; 2003 Sep; 198(6):863-8. PubMed ID: 12963694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VEGF-D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma.
    Thelen A; Scholz A; Benckert C; von Marschall Z; Schröder M; Wiedenmann B; Neuhaus P; Rosewicz S; Jonas S
    Int J Cancer; 2008 Jun; 122(11):2471-81. PubMed ID: 18338756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression of VEGF ligands and receptors in prostate cancer.
    Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
    Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
    Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of lymphangiogenesis by soluble vascular endothelial growth factor receptor-2 in a mouse lung cancer model.
    Maehana S; Nakamura M; Ogawa F; Imai R; Murakami R; Kojima F; Majima M; Kitasato H
    Biomed Pharmacother; 2016 Dec; 84():660-665. PubMed ID: 27697638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
    Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
    Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of VEGF-C and VEGF-D as significant markers for assessment of lymphangiogenesis and lymph node metastasis in non-small cell lung cancer.
    Feng Y; Wang W; Hu J; Ma J; Zhang Y; Zhang J
    Anat Rec (Hoboken); 2010 May; 293(5):802-12. PubMed ID: 20225197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology.
    Harris NC; Davydova N; Roufail S; Paquet-Fifield S; Paavonen K; Karnezis T; Zhang YF; Sato T; Rothacker J; Nice EC; Stacker SA; Achen MG
    J Biol Chem; 2013 Mar; 288(12):8176-8186. PubMed ID: 23404505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.
    Mu J; Abe Y; Tsutsui T; Yamamoto N; Tai XG; Niwa O; Tsujimura T; Sato B; Terano H; Fujiwara H; Hamaoka T
    Jpn J Cancer Res; 1996 Sep; 87(9):963-71. PubMed ID: 8878460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.
    Whitehurst B; Flister MJ; Bagaitkar J; Volk L; Bivens CM; Pickett B; Castro-Rivera E; Brekken RA; Gerard RD; Ran S
    Int J Cancer; 2007 Nov; 121(10):2181-91. PubMed ID: 17597103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma.
    Arinaga M; Noguchi T; Takeno S; Chujo M; Miura T; Uchida Y
    Cancer; 2003 Jan; 97(2):457-64. PubMed ID: 12518370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias.
    Dias S; Hattori K; Heissig B; Zhu Z; Wu Y; Witte L; Hicklin DJ; Tateno M; Bohlen P; Moore MA; Rafii S
    Proc Natl Acad Sci U S A; 2001 Sep; 98(19):10857-62. PubMed ID: 11553814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.